Literature DB >> 30097523

Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.

K Ina Ly1, Derek H Oakley2, Alexander B Pine3, Matthew P Frosch2, Sy Han Chiou4, Rebecca A Betensky4, Stuart R Pomerantz5, Fred H Hochberg6, Tracy T Batchelor7, Daniel P Cahill8, Jorg Dietrich1.   

Abstract

BACKGROUND: The 2016 World Health Organization Classification of Central Nervous System Tumors categorizes gliomatosis cerebri growth pattern (GC) as a subgroup of diffuse infiltrating gliomas, defined by extent of brain involvement on magnetic resonance imaging (MRI). Clinical and radiographic features in GC patients are highly heterogeneous; however, prognosis has historically been considered poor. SUBJECTS, MATERIALS, AND METHODS: We performed a retrospective search for patients at our institution meeting radiographic criteria of primary, type I GC (defined as diffuse tumor infiltration without associated tumor mass and contrast enhancement on MRI) and analyzed their clinical, imaging, and histopathologic features.
RESULTS: A total of 34 patients met radiographic criteria of primary, type I GC, and 33 had a confirmed histologic diagnosis of an infiltrating glial neoplasm. Age >47 years at diagnosis was associated with worse overall survival (OS) compared with age ≤47 years (hazard ratio [HR] 1.04, 95% confidence interval [CI] 1.01-1.07, p = .003). Patients with grade 2 tumors demonstrated a trend for improved OS compared with those with grade 3 tumors (HR 2.65, 95% CI 0.99-7.08, p = .051). Except for brainstem involvement, extent or location of radiographic involvement did not detectably affect clinical outcome. IDH mutation status identified a subgroup of GC patients with particularly long survival up to 25 years and was associated with longer time to progression (HR 4.81, 95% CI 0.99-23.47, p = .052).
CONCLUSION: Patients with primary, type I GC do not uniformly carry a poor prognosis, even in the presence of widespread radiographic involvement. Consistent with other reports, IDH mutation status may identify patients with improved clinical outcome. Molecular characterization, rather than MRI features, may be most valuable for prognostication and management of GC patients. IMPLICATIONS FOR PRACTICE: Patients with gliomatosis cerebri growth pattern (GC) constitute a challenge to clinicians, given their wide range of clinical, histologic, and radiographic presentation, heterogeneous outcome patterns, and the lack of consensus on a standardized treatment approach. This study highlights that radiographic extent of disease-albeit category-defining-does not detectably influence survival and that IDH mutations may impact clinical outcome. Practicing oncologists should be aware that select GC patients may demonstrate exceptionally favorable survival times and prognosticate patients based on molecular markers, rather than imaging features alone. © AlphaMed Press 2018.

Entities:  

Keywords:  Diffuse infiltrating gliomas; Gliomatosis cerebri; Isocitrate dehydrogenase; Magnetic resonance imaging; Molecular markers

Mesh:

Year:  2018        PMID: 30097523      PMCID: PMC6519760          DOI: 10.1634/theoncologist.2018-0086

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  34 in total

1.  Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.

Authors:  Sophie Taillibert; Catherine Chodkiewicz; Florence Laigle-Donadey; Massimo Napolitano; Stéphanie Cartalat-Carel; Marc Sanson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 2.  Radiation therapy approach in gliomatosis cerebri--case reports and literature review.

Authors:  E Horst; O Micke; M L Romppainen; J Pyhtinen; W Paulus; U Schäfer; C Rübe; N Willich
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

3.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.

Authors:  David E Reuss; Yasin Mamatjan; Daniel Schrimpf; David Capper; Volker Hovestadt; Annekathrin Kratz; Felix Sahm; Christian Koelsche; Andrey Korshunov; Adriana Olar; Christian Hartmann; Jaap C Reijneveld; Pieter Wesseling; Andreas Unterberg; Michael Platten; Wolfgang Wick; Christel Herold-Mende; Kenneth Aldape; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-05-12       Impact factor: 17.088

4.  Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Authors:  Christian Hartmann; Bettina Hentschel; Wolfgang Wick; David Capper; Jörg Felsberg; Matthias Simon; Manfred Westphal; Gabriele Schackert; Richard Meyermann; Torsten Pietsch; Guido Reifenberger; Michael Weller; Markus Loeffler; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2010-11-19       Impact factor: 17.088

5.  Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas.

Authors:  M C Chamberlain; J A Murovic; V A Levin
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

Review 6.  Gliomatosis cerebri: a review of 22 cases.

Authors:  G Edward Vates; Susan Chang; Kathleen R Lamborn; Michael Prados; Mitchel S Berger
Journal:  Neurosurgery       Date:  2003-08       Impact factor: 4.654

Review 7.  Gliomatosis cerebri presenting as intractable epilepsy during early childhood.

Authors:  M T Jennings; M Frenchman; T Shehab; M D Johnson; J Creasy; K LaPorte; W D Dettbarn
Journal:  J Child Neurol       Date:  1995-01       Impact factor: 1.987

8.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

9.  Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Authors:  Ulrich Herrlinger; David T W Jones; Martin Glas; Elke Hattingen; Dorothee Gramatzki; Moritz Stuplich; Jörg Felsberg; Oliver Bähr; Gerrit H Gielen; Matthias Simon; Dorothee Wiewrodt; Martin Schabet; Volker Hovestadt; David Capper; Joachim P Steinbach; Andreas von Deimling; Peter Lichter; Stefan M Pfister; Michael Weller; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2015-10-22       Impact factor: 17.088

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  1 in total

1.  Surgical treatment of diffuse and multi-lobes involved glioma with the assistance of a multimodal technique.

Authors:  Jiayu Liu; Hewen Chen; Xin Gao; Meng Cui; Lin Ma; Xiaoque Zheng; Bing Guan; Xiaodong Ma
Journal:  Sci Rep       Date:  2022-02-28       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.